

# Premature Ovarian Failure – Investigations, Protocols, and Ayurvedic Management with Clinical Cases.

Chavan Anjali V<sup>1</sup>, Dr. Bhalgat Madhuri<sup>2</sup>, Dr. Mehetre Kaustubh<sup>3</sup>

<sup>1</sup>PG Scholar, <sup>2</sup>Professor and HOD <sup>3</sup>Guide Professor,

Department of Prasutitantra evum strirog vidnyan.

SVNHT Ayurved Mahavidyalay, Rahuri Factory, Rahuri, Maharashtra, India

**Abstract:** *Premature Ovarian Failure (POF), also termed Primary Ovarian Insufficiency (POI), is defined as ovarian dysfunction before the age of 40 years, presenting with amenorrhea, estrogen deficiency, and infertility. Diagnosis requires menstrual history, hypergonadotropic hypogonadism, low ovarian reserve markers, and exclusion of genetic/autoimmune etiologies. Ayurveda correlates POF with Artava-kṣaya, Beeja-duṣṭi, Dhātu-kṣaya, and Vāta-vṛddhi conditions as explained in Charaka Samhita (Chikitsa Sthana 30/211)<sup>1</sup> and Aṣṭāṅga Hṛdaya (Sutra Sthana 12/1–3)<sup>2</sup>. This article reviews clinical features, investigations, protocols, Ayurvedic management strategies, and clinical outcomes*

**Keywords:** Premature Ovarian Insufficiency, Primary Ovarian Failure, Artava-kṣaya, Beeja-duṣṭi, Rasayana, Vata-dushti, Ayurvedic gynecology

## I. INTRODUCTION

Primary Ovarian Insufficiency affects 1–2% of women under 40 and is characterized by ovarian follicular depletion or dysfunction leading to menstrual irregularity, hypoestrogenism, and infertility<sup>3</sup>. The condition requires comprehensive evaluation due to its long-term metabolic, psychological, and reproductive consequences<sup>4</sup>.

In Ayurveda, menstrual and reproductive functions are governed by *Artava* and *Beeja*, supported by *Rasa* and *Shukra dhātus*. *Charaka* describes *Artava-kṣaya* with features of scanty/delayed menses and infertility (Chikitsa Sthana 30/211)<sup>1</sup>. *Beeja-duṣṭi*, responsible for anovulation or abnormal conception, is elaborated in *Charaka Sharira Sthana* 2/4–5<sup>5</sup>. *Apāna Vāta*, responsible for ovulation and menstruation, when vitiated leads to anovulation and amenorrhea as described in *Aṣṭāṅga Hṛdaya* (Sutra Sthana 12/1–3)<sup>2</sup>.

## II. REVIEW OF LITERATURE

### 1. Epidemiology

Primary Ovarian Insufficiency affects nearly **1 in 100 women by age 40** and **1 in 1000 by age 30**<sup>6</sup>. These figures highlight its early onset compared to natural menopause and its significance as a reproductive health issue.

### 2. Etiology

#### a. Genetic

Chromosomal defects such as **Turner syndrome**, and molecular abnormalities like the **FMR1 premutation**<sup>7</sup>, are recognized causes. These conditions disrupt follicular development and accelerate follicular loss.

#### b. Autoimmune

**Autoimmune oophoritis**<sup>8</sup> results from immune-mediated follicular destruction. It is often seen with other autoimmune disorders, suggesting systemic immune dysfunction.

#### c. Iatrogenic

Cancer therapies—**chemotherapy and radiotherapy**<sup>9</sup>—are known to be gonadotoxic, causing irreversible ovarian follicle depletion.



#### **d. Idiopathic**

Most POI cases remain **idiopathic**, indicating multifactorial or still-unidentified mechanisms.

#### **3. Pathophysiology**

The central mechanism is **accelerated follicular apoptosis or dysfunction**, resulting in **elevated FSH and reduced estradiol**<sup>10</sup>. Although follicles may persist, they often fail to respond effectively to gonadotropins, causing intermittent ovarian activity.

#### **4. Clinical Features**

- Amenorrhea / oligomenorrhea
- Hot flushes and night sweats
- Vaginal dryness and dyspareunia
- Decreased libido
- Infertility
- Mood instability
- Reduced bone mineral density

#### **5. Complications**

Long-standing estrogen deficiency results in:

- Osteoporosis
- Increased cardiovascular risk
- Persistent infertility
- Psychological distress and reduced quality of life

### **AYURVEDIC REVIEW OF LITERATURE**

#### **1. Artava-kṣaya**

Classical texts describe **delayed, scanty, or absent menstruation** with infertility, corresponding to Artava-kṣaya as explained in *Charaka Chikitsa Sthana 30/211*<sup>1</sup>. The condition arises from dhātu depletion, Vata aggravation, and improper nourishment of Artava.

#### **2. Beeja-duṣṭi**

*Charaka Sharira Sthana 2/4–5*<sup>5</sup> describes vitiation of the ovum leading to infertility and abnormal conception. This aligns with modern genetic and chromosomal abnormalities affecting ovarian reserve.

#### **3. Artavavaha Srotas & Srotodushti**

Disturbances like **Sanga, Vimargagamana, Atipravṛtti** described in *Charaka Vimana Sthana 5/8*<sup>11</sup> can be correlated with anovulation, follicular arrest, or hormonal imbalance affecting menstrual physiology.

#### **4. Role of Vata**

According to *Aṣṭāṅga Hṛdaya Sutra Sthana 12/1–3*<sup>2</sup>, **Apāna Vāta** governs menstruation, ovulation, and reproductive organs. Its vitiation results in amenorrhea, Artava-kṣaya, and ovulatory disturbances—conceptually parallel to ovarian axis dysfunction.

#### **5. Rasayana & Stree-prasādana Yogas**

Rejuvenative therapies such as Shatavari, Jeevanti, Ashwagandha, and formulations like **Phala Ghrita (Uttar Tantra 33/8–10)**<sup>12</sup> and Putrajeevak are described to nourish reproductive tissues and enhance fertility.



## CLINICAL FEATURES

Women with Primary Ovarian Insufficiency commonly present with amenorrhea or oligomenorrhea due to impaired ovarian activity, along with subfertility or infertility resulting from disrupted folliculogenesis. The decline in estrogen leads to classic vasomotor symptoms such as hot flushes and night sweats, accompanied by vaginal dryness and dyspareunia due to urogenital atrophy. Psychological manifestations are frequent, including mood disturbances, irritability, and emotional instability, while sleep disturbances occur due to neuroendocrine dysregulation. Long-standing estrogen deficiency further contributes to osteopenia and osteoporosis, reflecting compromised bone health described in both modern medicine and Ayurvedic concepts of dhātu-kṣaya.

## INVESTIGATIONS

### 1. Hormonal Profile

- **FSH >25 IU/L** on two occasions 4–6 weeks apart<sup>13</sup>
- Low **estradiol (<50 pg/mL)**
- Elevated LH
- Decreased **AMH (<1 ng/mL)**<sup>14</sup>

### 2. Ovarian Reserve

- AMH
- Antral follicle count (AFC)
- Ovarian volume

### 3. Imaging

- Transvaginal ultrasonography for AFC and ovarian size
- Doppler study if vascular compromise suspected

### 4. Genetic Tests

- Karyotyping (Turner syndrome)
- **FMR1 premutation**<sup>15</sup>

### 5. Autoimmune Evaluation

- Anti-ovarian antibodies
- Thyroid autoantibodies
- Adrenal antibodies

### 6. Bone Health

- DEXA scan
- Vitamin D & calcium levels

## MODERN MANAGEMENT PROTOCOLS

### 1. Hormone Replacement Therapy

Combined **estrogen–progesterone therapy** supports cardiovascular and bone health and relieves hypoestrogenic symptoms<sup>16</sup>.

### 2. Fertility Treatment

- Poor response to ovulation induction
- **IVF with donor oocyte** remains the most effective option<sup>17</sup>

### 3. Bone Health Management

- Calcium + Vitamin D
- Bisphosphonates for severe bone demineralization<sup>18</sup>

### 4. Psychological Support

Counseling helps manage emotional distress, coping challenges, and sexual health issues.



## AYURVEDIC MANAGEMENT PROTOCOL

### 1. Śodhana Therapy

#### Basti Chikitsa

Main therapy for Apāna Vāta disorders.

- **Kṣheera Basti** – nourishing
- **Yāpana Basti** – Rasayana, dhātu-building
- **Phala-Ghrita Basti** – fertility-enhancing (*Aṣṭāṅga Hṛdaya, Uttar Tantra 33/8–10<sup>12</sup>*)

### 2. Śamana Therapy

Key formulations:

- Shatavari Kalpa<sup>19</sup>
- Ashwagandha Churna
- Phala Ghrita<sup>12</sup>
- Putrajeevak Beej
- Kanchanar Guggulu<sup>20</sup>
- Ashokarishta

These address Vata imbalance and strengthen reproductive tissues.

### 3. Rasayana Therapy

- Chyawanprash
- Amalaki Rasayana
- Suvarna-yogas (under supervision)

These improve Ojas, general vitality, and reproductive strength.

### 4. Diet & Lifestyle

- Milk, ghee, sesame, nuts, and iron-rich foods
- Avoid Vata-aggravating factors
- **Yoga:** Baddhakonasana, Bhujangasana
- **Pranayama:** Anulom-Vilom, Bhramari

## CLINICAL CASES

### CASE 1:

#### Primary Ovarian Insufficiency With Ayurvedic Management (Successful Cycle Restoration)

##### 1. Patient Profile

**Age:** 28 years

**Marital Status:** Married for 3 years

**Occupation:** School teacher

##### Presenting Complaints:

Amenorrhea for 8 months

Hot flushes, night sweats for 3 months

Vaginal dryness

Fatigue, low mood

Primary infertility

##### 2. History

Menstrual history reveals initially regular 28–30-day cycles until 25 years of age. Gradual oligomenorrhea developed, followed by complete amenorrhea. No history of chemotherapy, radiotherapy, pelvic surgery, or infection. No family history of early menopause. Diet predominantly irregular, high mental stress, poor sleep.

Ayurvedic assessment shows **vata-prakopa** features: dryness, insomnia, constipation, anxiety.

Copyright to IJARSCT

[www.ijarsct.co.in](http://www.ijarsct.co.in)



DOI: 10.48175/IJARSCT-30035



### 3. Examination

BMI: 22.4 kg/m<sup>2</sup>

Pulse: 86/min

Blood pressure: 110/74 mmHg

Mild vaginal atrophy

No hirsutism or acne

Thyroid normal on clinical evaluation

### 4. Investigations

#### Hormonal profile:

FSH: 46 IU/L (two readings 6 weeks apart)

LH: 28 IU/L

Estradiol (E2): 32 pg/mL

AMH: 0.18 ng/mL

Prolactin: Normal

TSH, TPO antibodies: Normal

#### Ultrasound pelvis:

Small ovaries

Reduced antral follicle count: AFC = 2 (both ovaries combined)

Thin endometrium (3 mm)

#### Bone health tests:

DEXA: Early osteopenia

### 5. Diagnosis

**Modern:** Primary Ovarian Insufficiency (POI)

#### Ayurvedic:

*Artava-kṣaya, Beeja-kṣaya*

*Apāna Vāta dushti*

*Asthī dhātu kṣaya*

*Artavavaha srotas sanga*

### 6. Treatment Protocol

#### A. Śodhana (Bio-purification)

##### 1. Kṣīra Basti (14 days)

To nourish reproductive tissues and pacify Apāna Vāta.

##### 2. Yāpana Basti (8 days)

Rasayana effect; indicated for reproductive depletion.

#### B. Śamana Chikitsā

##### Internal medications:

**Shatavari Kalpa** – 10 g twice daily

**Ashwagandha churna** – 3 g twice daily

**Phala Ghrita** – 1 tsp twice daily

**Putrajeevak Beej** – 2 g daily

**Aśokāriṣṭa** – 20 ml twice daily

**Kanchanar Guggulu** – for srotoshodhana

##### Diet:

Ghee, milk, black sesame, almonds, dates, jaggery

Warm, unctuous food; avoidance of cold, dry, and fasting regimen

##### Lifestyle + Yoga:

Baddha Konasana, Setu Bandhasana, Vajrasana

Pranayama: Anulom-Vilom, Bhramari

Copyright to IJAR SCT

[www.ijarsct.co.in](http://www.ijarsct.co.in)



DOI: 10.48175/IJAR SCT-30035



Yoga Nidra for stress modulation

### 7. Follow-Up and Outcome

**After 6 weeks:** Reduction in hot flushes, better sleep, improved vaginal lubrication.

**After 3 months:** Spontaneous withdrawal bleed recorded; endometrium improved (5.2 mm).

**After 6 months:** Cycles restored to 35–40 days. FSH reduced to **22 IU/L**, Estradiol rose to **52 pg/mL**.

**AFC improved to 4**, osteopenia marginally improved.

**Outcome:** Partial restoration of ovarian function, improved quality of life, and potential for natural conception.

### CASE 2:

#### POI With Infertility – Integrative Approach + Donor Oocyte IVF

##### 1. Patient Profile

**Age:** 32 years

**Marital Status:** Married for 6 years

##### Presenting Complaints:

Irregular scanty menses for 2 years

Amenorrhea since last 7 months

Infertility

Emotional stress, anxiety, insomnia

Vaginal dryness

##### 2. History

Menarche at 13 years. Initially regular cycles, but increasing irregularity began after 29 years. No major illness.

Moderate stress, high workload. Diet low in nutrition; often skipped meals.

Ayurvedic prakriti: Vata-Pitta predominant.

Symptoms suggest **Vata-Pitta prakopa** and **Artava-kshaya**.

##### 3. Examination

BMI: 20.8 kg/m<sup>2</sup>

Pulse: 92/min

BP: 112/70 mmHg

Dry skin, brittle nails

Psychological distress evident

##### 4. Investigations

###### Hormonal profile:

FSH: **62 IU/L**

LH: **35 IU/L**

Estradiol: **18 pg/mL**

AMH: **0.05 ng/mL**

TSH: Slightly raised

Anti-ovarian antibodies: Positive

###### Ultrasound pelvis:

Ovaries markedly small

AFC = 0–1

Thin endometrium (2.5 mm)

**Genetic workup:** Normal

**DEXA:** Mild osteopenia

##### 5. Diagnosis

**Modern:** Autoimmune-mediated POI

**Ayurvedic:**

Copyright to IJARSCT

[www.ijarsct.co.in](http://www.ijarsct.co.in)



DOI: 10.48175/IJARSCT-30035



*Artava-kṣaya with Beeja-duṣṭi*  
*Vata-Pitta prakopa*  
*Artavavaha srotodushti (Sanga + Kshaya)*  
*Rasa-Rakta dhatu kshaya*

## 6. Treatment Protocol

### A. Ayurvedic Interventions

#### 1. Śamana Therapy (8 months)

**Shatavari ghrita** – 1 tsp twice daily

**Ashwagandha tablets** – 500 mg twice daily

**Drakshadi Kashaya** – for Pitta-pacification

**Guduchi + Shatavari + Yashtimadhu** – Rasayana

**Phala ghrita** – to improve endometrial quality

#### 2. Basti Therapy

**Kṣheera Basti (16 days)**

**Anuvasana with sesame oil** on alternate days

#### 3. Diet & Lifestyle

Ghee-based diet, warm food

Avoid late nights, fasting, excessive travel

Pranayama: Nadi-shodhana, Ujjayi

Yoga Nidra for stress reduction

### B. Modern Interventions

#### 1. Hormone Replacement Therapy

Low-dose estrogen + cyclic progesterone to maintain bone and cardiovascular health.

#### 2. Fertility Management

Due to very low AMH and absent follicles:

**Advised IVF with donor oocyte**

Endometrial preparation supported by Ayurvedic Rasayana and modern HRT

## 7. Follow-Up and Outcome

**After 3 months:** Reduction in vasomotor symptoms; improved mood and sleep.

**After 5 months:** Endometrial thickness improved to **6.8 mm** with combined therapy.

**After 8 months:** Patient underwent donor-oocyte IVF; embryo transfer successful.

**Pregnancy confirmed at 6 weeks.**

Continued Ayurvedic support therapy for stress, digestion, and Vata regulation.

**Outcome:** Conception achieved through integrative modern–Ayurvedic approach with improved endometrial receptivity and emotional wellbeing.

## II. DISCUSSION

Primary Ovarian Insufficiency (POI) is an early-onset ovarian failure affecting about 1% of women under 40, arising from genetic factors such as Turner syndrome and FMR1 premutation, autoimmune ovarian injury, gonadotoxic cancer therapies, or idiopathic causes. The central mechanism involves accelerated follicular apoptosis and impaired follicular responsiveness, resulting in elevated FSH, low estradiol, and intermittent ovarian activity. Clinically, women present with amenorrhea or oligomenorrhea, infertility, vasomotor symptoms, vaginal dryness, mood disturbances, and long-term risks such as osteoporosis and cardiovascular compromise due to chronic hypoestrogenism. Ayurvedic texts describe a parallel condition under Artava-kṣaya, where dhātu-kṣaya and Vata aggravation impair menstrual flow and fertility. Beeja-duṣṭi correlates with genetic abnormalities, while Artavavaha Srotodushti (Sanga, Vimargagamana)





reflects anovulation and hormonal dysregulation. Apāna Vāta's dysfunction mirrors modern ovarian axis failure, explaining amenorrhea, follicular arrest, and reproductive decline.

Modern diagnosis relies on high FSH, low estradiol, low AMH, reduced antral follicle count, and supportive genetic or autoimmune markers. Management includes hormone replacement therapy to restore estrogen balance, donor-oocyte IVF for fertility, bone preservation strategies, and psychological support. Ayurveda offers a comprehensive, restorative approach focusing on nourishing depleted dhātus and correcting Vata. Basti Chikitsa—especially Kṣheera Basti, Yāpana Basti, and Phala Ghrita Basti—supports Rasayana action and reproductive rejuvenation. Śamana therapies with Shatavari, Ashwagandha, Phala Ghrita, Putrajeevak, and Ashokarishta strengthen Artava dhātu and stabilize hormonal balance. Rasayana formulations enhance Ojas and systemic vitality, while diet, ghee, milk, sesame, and yoga practices like Baddhakonasana and Anulom-Vilom further harmonize Apāna Vāta. Thus, integrating modern hormone therapy with Ayurvedic Vata-pacifying, dhātu-nourishing, and Rasayana strategies provides a synergistic model for improving reproductive function, systemic health, and quality of life in women with POI.

The two clinical cases highlight the multifactorial nature of Primary Ovarian Insufficiency and the potential benefits of an integrative Ayurvedic-modern approach. In the first case, a 28-year-old woman with classic features of POI—amenorrhea, vasomotor symptoms, low estradiol, elevated gonadotropins, and reduced AFC—demonstrated significant improvement with Ayurvedic management alone. Her presentation aligned with Artava-kṣaya, Apāna Vāta dushti, and dhātu-kṣaya, reflected by dryness, constipation, irregular sleep, and depleted reproductive tissue parameters. The therapeutic regimen incorporating Kṣīra Basti, Yāpana Basti, Shatavari, Ashwagandha, Phala Ghrita, and Vata-pacifying diet and yoga resulted in improved hormonal balance, endometrial thickness, follicular count, and spontaneous menstrual restoration. This supports the Ayurvedic concept that Basti strengthens Apāna Vāta, facilitates proper srotas function, and nourishes depleted reproductive dhātus, thereby restoring partial ovarian activity even in low-reserve states.

In the second case, a 32-year-old woman with autoimmune-mediated POI demonstrated more severe ovarian compromise, reflected by extremely low AMH, high FSH, nearly absent follicles, and positive autoimmune markers. Her Ayurvedic diagnosis of Artava-kṣaya with Beeja-duṣṭi, Vata-Pitta prakopa, and Rasa-Rakta dhātu-kṣaya required a more intensive Rasayana and Pitta-Vata pacifying regimen. Prolonged Śamana therapy, Rasayana combinations, Kṣheera Basti, and endometrial-nourishing ghrithas improved systemic symptoms and endometrial receptivity, although ovarian activity remained poor. The integration of modern HRT stabilized hormonal milieu and bone health, while donor-oocyte IVF offered the only viable fertility option. Notably, Ayurveda significantly supported endometrial preparation, emotional stability, and physiological strength, contributing to a successful conception following embryo transfer.

Together, these cases demonstrate that Ayurvedic therapies play a pivotal role in modulating Vata, revitalizing dhātus, and improving systemic and reproductive health. While early-stage POI may show partial restoration of ovarian function with robust Ayurvedic treatment, advanced POI—especially autoimmune or near-zero follicular reserve—benefits most from an integrative model where Ayurveda optimizes hormonal balance, endometrial quality, stress response, and overall fertility outcomes. These observations reinforce that Ayurveda offers substantial supportive and restorative potential, particularly in enhancing quality of life, cycle regularity, and fertility preparedness, even when modern interventions such as donor-oocyte IVF are required for conception.

### III. CONCLUSION

Premature Ovarian Failure, or Primary Ovarian Insufficiency, is a complex reproductive disorder with significant endocrine, metabolic, and psychosocial implications. Modern understanding highlights diverse etiologies—including genetic defects, autoimmune processes, iatrogenic ovarian injury, and idiopathic mechanisms—culminating in accelerated follicular depletion and impaired ovarian responsiveness. Accurate diagnosis through hormonal assays, ovarian reserve markers, genetic analysis, and imaging is essential for timely management. Contemporary treatment focuses on hormone replacement therapy for symptom relief and long-term health preservation, while donor-oocyte IVF remains the most reliable fertility option for women with severely diminished ovarian reserve.





Ayurveda provides a complementary and restorative paradigm that addresses the deeper pathophysiological roots through concepts such as Artava-kṣaya, Apāna Vāta dushti, Beeja-duṣṭi, and srotodushti. Basti therapies, Rasayana interventions, and Vata-pacifying śamana measures collectively nourish depleted dhātus, stabilize hormonal balance, improve endometrial quality, and enhance overall reproductive vitality. The clinical cases presented illustrate how individualized Ayurvedic therapy can restore menstrual cyclicity and partial ovarian activity in early POI, while also significantly improving endometrial receptivity, psychological wellbeing, and treatment outcomes in advanced autoimmune or end-stage POI when integrated with modern reproductive technologies.

Overall, an integrative approach—combining precise modern diagnostics and necessary hormonal or ART interventions with holistic Ayurvedic Rasayana and Vata-shamana therapies—offers a comprehensive and patient-centered protocol. This synergistic model not only improves reproductive outcomes but also enhances systemic health, emotional resilience, and quality of life, establishing Ayurveda as a valuable adjunct in the multidisciplinary management of Premature Ovarian Failure.

### REFERENCES

- [1]. Agnivesha, Charaka. *Charaka Saṃhitā*, Chikitsa Sthana 30/211. Edited by Jadavji Trikamji. Varanasi: Chaukhambha Orientalia; 2020. p. 652.
- [2]. Vāgbhaṭa. *Aṣṭāṅga Hṛdaya*, Sutra Sthana 12/1–3. Edited by Kunte AM, Navare VS. 9th Reprint ed. Varanasi: Chaukhambha Orientalia; 2002. p. 682.
- [3]. Sushruta. *Sushruta Samhita*, Sharira Sthana 2/33. Chaukhambha Sanskrit Sansthan; 2012. p. 52.
- [4]. Bhavamishra. *Bhavaprakasha*, Purva Khanda, Stree Roga Adhyaya. Chaukhambha Bharati Academy; 2010. p. 312.
- [5]. Agnivesha. *Charaka Samhita*, Sharira Sthana 2/4–5. Varanasi: Chaukhambha Surbharati; 2017. p. 314.
- [6]. Charaka. *Charaka Samhita*, Vimana Sthana 5/8. Chaukhambha Orientalia; 2018. p. 415.
- [7]. Vāgbhaṭa. *Ashtanga Hridaya*, Uttara Tantra 33/8–10. Chaukhambha Orientalia; 2002. p. 845.
- [8]. Chakrapani Datta. *Chakradatta*, Yonivyapad Chikitsa. Chaukhambha; 2011. p. 178.
- [9]. Nelson LM. Primary Ovarian Insufficiency. *N Engl J Med*. 2009;360:606–14.
- [10]. Coulam CB. Premature ovarian failure. *Fertil Steril*. 1982;38:645–55.
- [11]. Torrealday S, Kodaman P, Pal L. Premature ovarian insufficiency. *Endocrinol Metab Clin*. 2015;44:543–57.
- [12]. Welt CK. Primary ovarian insufficiency update. *Clin Endocrinol*. 2008;68:499–509.
- [13]. ACOG Committee Opinion No. 605. *Obstet Gynecol*. 2014;124:193–7.
- [14]. Gleicher N, Barad DH. Ovarian reserve testing. *Fertil Steril*. 2011;96:943–50.
- [15]. Welt CK et al. Fragile X premutation and POI. *Fertil Steril*. 2004;82:948–55.
- [16]. Popat VB et al. HRT in POI. *J Clin Endocrinol Metab*. 2014;99:784–90.
- [17]. Conforti A et al. IVF in POI. *Reprod Biol Endocrinol*. 2021;19:1–12.
- [18]. Compston J. Bone disease in estrogen deficiency. *J Bone Miner Res*. 2016;31:1486–93.
- [19]. Sharma PV. *Dravyaguna Vijnana*. Chaukhambha; 1995. p. 312.
- [20]. Vishwanath Dwivedi. *Ayurvedic Pharmacology of Guggulu*. Chaukhambha; 2012. p. 210.

